TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics is positioned for long-term success with their diverse research pipeline and recent FDA approval for BRIUMVI, which has a positive outlook in the treatment of relapsing forms of multiple sclerosis. The company's current financials, including their estimated EPS of $1.30 and operating expenses of $629M in 2026, demonstrate strong potential for growth. Risks for the company include potential safety concerns and competition in the market, but the initiation of their Phase 2 trial for treatment-resistant schizophrenia presents a high-risk/high-reward opportunity. Additionally, positive results from the Phase 3b ENHANCE trial and promising data from the ongoing Phase 4 ENABLE study further reinforce TG Therapeutics' favorable profile for BRIUMVI in the real-world RMS setting. With a strong cash position and a successful completion of their share repurchase program, TG Therapeutics is well-positioned for continued success in the future.

TG Therapeutics is facing stiff competition in the B-cell disease market, with other drugs such as Ocrevus and Kesimpta already approved and gaining traction. The company's recent approval for BRIUMVI will likely face challenges in gaining market share, as physicians and insurance companies are more likely to stick with established treatments in order to minimize risk. Additionally, the company's strategy for differentiation through a single infusion process may not be as impactful as anticipated, as KOLs and physicians have stated that it is not a crucial factor for patients. The growing landscape of new SC and oral options, including Roche's BTK inhibitor and Novartis' Q8W version of Kesimpta, further adds to the competitive pressure for TG Therapeutics.